Xtant Medical Holdings
XTNT
Market cap $87.4M

0.6300 USD

-0.0020

0.32%

At close Oct 4, 4:00 PM EDT

After hours

0.6300

+0.0000

0%

1 day

-0.32%

5 days

-4.55%

1 month

8.62%

3 months

-4.28%

6 months

-36.77%

Year to date

-47.93%

1 year

-43.75%

5 years

-77.50%

About: Xtant Medical Holdings Inc is a medical technology company focused on the design, development, and commercialization of a comprehensive portfolio of orthobiologics and spinal implant systems to facilitate spinal fusion in complex spine, deformity and degenerative procedures. Its products are used by orthopedic spine surgeons and neurosurgeons to treat a variety of spinal disorders in the cervical, thoracolumbar, and interbody spine. The company's biomaterial products include OsteoSponge, OsteoSponge SC, OsteoSelect Plus DBM putty, OsteoWrap, and the line of 3Demin products, as well as other allografts. It generates a majority of its revenue from the US.

Employees: 215

Healthcare Biological Products, Except Diagnostic Substances

0

Funds holding %

of 6,728 funds

–

Analysts bullish %

Fund manager confidence

Based on 2024 Q2 SEC filings by fund managers ($100M+ AUM)

2.43% more ownership

Funds ownership: 69.46% [Q1] → 71.89% (+2.43%) [Q2]

18% less funds holding

Funds holding: 33 [Q1] → 27 (-6) [Q2]

36% less repeat investments, than reductions

Existing positions increased: 7 | Existing positions reduced: 11

44% less capital invested

Capital invested by funds: $106M [Q1] → $59M (-$46.7M) [Q2]

75% less first-time investments, than exits

New positions opened: 2 | Existing positions closed: 8

100% less funds holding in top 10

Funds holding in top 10: 2 [Q1] → 0 (-2) [Q2]

See Fund Rankings

Research analyst outlook

We haven’t received any recent analyst ratings for XTNT.

See Analyst Rankings

Financial journalist opinion

Xtant Medical Expands Product Portfolio with the Launch of the Cortera(R) Posterior Fixation System

New System Enhances Surgical Efficiency and Provides Versatile Solutions for Complex Spine Procedures BELGRADE, MT / ACCESSWIRE / September 23, 2024 / Xtant Medical Holdings, Inc. (NYSE American:XTNT), a leading global medical technology company focused on the treatment of spinal disorders, is excited to announce the launch of the Cortera Posterior Fixation System, a comprehensive solution designed to streamline thoracolumbar fixation surgeries. Now available to surgeons across the United States through Xtant's commercial channels.

Xtant Medical Expands Product Portfolio with the Launch of the Cortera(R) Posterior Fixation System

Xtant Medical Expands Product Portfolio with Launch of its own Viable Bone Matrix, OsteoVive(R) Plus

New Cellular Bone Matrix Designed with Cohesive and Moldable Handling Characteristics BELGRADE, MT / ACCESSWIRE / September 18, 2024 / Xtant Medical Holdings, Inc. (NYSE American:XTNT), a global medical technology company focused on surgical solutions for the treatment of spinal disorders, today announced it has launched a new addition to its robust product portfolio, OsteoVive Plus, a moldable, viable bone matrix that can be used in a variety of grafting procedures. The graft is now available, to the company's nationwide distribution network of independent agents as well as original equipment manufacturer relationships.

Xtant Medical Expands Product Portfolio with Launch of its own Viable Bone Matrix, OsteoVive(R) Plus

Xtant Medical Holdings, Inc. (XTNT) Q2 2024 Earnings Call Transcript

Xtant Medical Holdings, Inc. (NYSE:XTNT ) Q2 2024 Earnings Conference Call August 9, 2024 9:00 AM ET Company Participants Brett Maas - IR Sean Browne - President and CEO Scott Neils - CFO Conference Call Participants Ryan Zimmerman - BTIG Chase Knickerbocker - Craig-Hallum Capital Operator Welcome to the Xtant Medical Holdings, Inc. Second Quarter 2024 Conference Call. [Operator Instructions] I would now like to turn the call over to your host, Brett Maas, IR.

Xtant Medical Holdings, Inc. (XTNT) Q2 2024 Earnings Call Transcript

Xtant Medical Announces Closing of $5.0 Million Private Placement

BELGRADE, MT / ACCESSWIRE / August 9, 2024 / Xtant Medical Holdings, Inc. (NYSE American:XTNT), a global medical technology company focused on surgical solutions for the treatment of spinal disorders, today announced the closing of its previously announced $5.0 million private placement with an existing institutional investor. The Company sold 7,812,500 shares of common stock at a purchase price of $0.64 per share.

Xtant Medical Announces Closing of $5.0 Million Private Placement

Xtant Medical Announces $5.0 Million Private Placement

BELGRADE, MT / ACCESSWIRE / August 8, 2024 / Xtant Medical Holdings, Inc. (NYSE American:XTNT), a global medical technology company focused on surgical solutions for the treatment of spinal disorders, today announced it has entered into a securities purchase agreement with an existing institutional investor to sell shares of its common stock in a private placement. The Company agreed to issue an aggregate of 7,812,500 shares of common stock at a purchase price of $0.64 per share, resulting in gross proceeds of $5.0 million.

Xtant Medical Announces $5.0 Million Private Placement

Xtant Medical to Host Second Quarter 2024 Financial Results Earnings Conference call on August 9, 2024

BELGRADE, MT / ACCESSWIRE / August 8, 2024 / Xtant Medical Holdings, Inc. (NYSE American:XTNT), a global medical technology company focused on surgical solutions for the treatment of spinal disorders, today announced that it will release its financial results for the second quarter ended June 30, 2024, after the close of the financial markets on Thursday, August 8, 2024. Sean Browne, President and Chief Executive Officer, and Scott Neils, Chief Financial Officer, will host a conference call on Friday, August 9, 2024, at 9:00 AM ET to review results.

Xtant Medical to Host Second Quarter 2024 Financial Results Earnings Conference call on August 9, 2024

Xtant Medical Reports Second Quarter 2024 Revenue Growth of 48%

BELGRADE, MT / ACCESSWIRE / August 8, 2024 / Xtant Medical Holdings, Inc. (NYSE American: XTNT), a global medical technology company focused on surgical solutions for the treatment of spinal disorders, today reported financial and operating results for the second quarter ended June 30, 2024. Second Quarter 2024 Financial Highlights Revenue of $29.9 million, up 48%, compared to the prior year quarter Gross margin of 62.1%, up 50 basis points, compared to the prior year quarter Net loss of $3.9 million compared to $2.2 million in the year ago quarter Positive Adjusted EBITDA; Adjusted EBITDA of $0.5 million compared to $0.1 million in the prior year quarter Recent Business Highlights Recently launched two new amniotic membrane allografts products, SimpliGraft™ and SimpliMax™; while Cortera™ reached record sales and users for the second quarter Signed 15 new distributors in the second quarter Awarded 20 IDN contracts in the second quarter Entered into a $5.0 million private placement on August 7, 2024 Sean Browne, President and CEO of Xtant Medical, stated, "Our second quarter financial results illustrate the positive momentum that is building as we head into the second half of 2024.

Xtant Medical Reports Second Quarter 2024 Revenue Growth of 48%

Xtant Medical to Present at the Canaccord Genuity 44th Annual Growth Conference & Private Company Showcase

BELGRADE, MT / ACCESSWIRE / July 25, 2024 / Xtant Medical Holdings, Inc. (NYSE American:XTNT), a global medical technology company focused on surgical solutions for the treatment of spinal disorders, today announced that Sean Browne, President and Chief Executive Officer, and Scott Neils, Chief Financial Officer, will attend the Canaccord Genuity 44th Annual Growth Conference & Private Company Showcase being held August 13-15, 2024 at the InterContinental Boston, an IHG Hotel. Sean Browne, President and Chief Executive Officer will present on Wednesday, August 14th at 11:00 a.m.

Xtant Medical to Present at the Canaccord Genuity 44th Annual Growth Conference & Private Company Showcase

Xtant Medical Holdings, Inc. (XTNT) Q1 2024 Earnings Call Transcript

Xtant Medical Holdings, Inc. (NYSE:XTNT ) Q1 2024 Results Conference Call May 15, 2024 4:30 PM ET Company Participants Brett Maas - Managing Partner, Hayden IR Sean Browne - President and Chief Executive Officer Scott Neils - Chief Financial Officer Conference Call Participants Ryan Zimmerman - BTIG Chase Knickerbocker - Craig-Hallum Operator Greetings. Welcome to the Xtant Medical Holdings, Inc. First Quarter 2024 Conference Call.

Xtant Medical Holdings, Inc. (XTNT) Q1 2024 Earnings Call Transcript

Xtant Medical Reports First Quarter 2024 Revenue Growth of 55% and Raises Full Year 2024 Revenue Guidance

Expects Revenue for Full Year 2024 of $116 Million to $120 Million BELGRADE, MT / ACCESSWIRE / May 15, 2024 / Xtant Medical Holdings, Inc. (NYSE American:XTNT), a global medical technology company focused on surgical solutions for the treatment of spinal disorders, today reported financial and operating results for the first quarter ended March 31, 2024. First Quarter 2024 Financial Highlights Revenue of $27.9 million, up 55%, compared to the prior year quarter Gross margin of 62.1%, up 340 basis points, compared to the prior year quarter Net loss of $4.4 million compared to $2.1 million in the year ago quarter Positive Adjusted EBITDA; Adjusted EBITDA of $0.1 million compared to an Adjusted EBITDA loss of $0.3 million in the prior year quarter Recent Business Highlights Launched two amniotic membrane allografts, SimpliGraft™ and SimpliMax™ Amended its Term Credit and Revolving Credit Agreements to provide additional working capital Sean Browne, President and CEO of Xtant Medical, stated, "In the first quarter of 2024, we delivered strong revenue growth of 55% and positive Adjusted EBITDA, despite continued near-term supply chain challenges for our biologics and spinal hardware product families.

Xtant Medical Reports First Quarter 2024 Revenue Growth of 55% and Raises Full Year 2024 Revenue Guidance

See News Rankings

Charts implemented using Lightweight Charts™